

May 17, 2022

Reviewer #1:

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Accept (General priority) Specific Comments to Authors: Very interesting clinical case, will help to expand the understanding of irAEs.

Reviewer #2:

Scientific Quality: Grade B (Very good)

Language Quality: Grade A (Priority publishing)

Conclusion: Accept (General priority)

Specific Comments to Authors: Tanaka et al. reported an interesting case of delayed Immune-Related Sclerosing Cholangitis After Discontinuation of Pembrolizumab. The case is original and no other similar case exist on the literature to date. The paper is concise, well written and well documented including immunological, imaging and histopathologic data allowing to exclude alternative diagnosis, especially chemotherapy-induced SP. Despite no conclusion can be made based on only one case report, this report contribute to improve knowledge about delayed irAEs after ICIs. I have no major or minor comments.

To the reviewers:

We sincerely thank the peer reviewers for their time and thoughtful comments in consideration of our manuscript (Manuscript NO.: 76869, Case Report).